Melanoma: An expert view beyond single-agent checkpoint blockade

Speaker: Jean Jacques Grob

JJ Grob discusses the CheckMate 067 update presented at ASCO 2016 Annual Meeting. He says that combination immunotherapy might not be better than single agent nivolumab in term of progression-free survival at least in melanoma patients with PD-L1 expression more than 5%, but he is concerned on how this test is reliable. Overall survival data are expected by the end of year. Immunotherapy transformed the care with melanoma patients living longer, therefore optimising strategies to decrease the toxicity profile are needed. Abstract 9505: Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

Discussion Points

  1. Rationale for the study
  2. Key study findings
  3. Practice perspective

Abstract 9505: Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).